TECAR therapy for Peyronie's disease: a phase-one prospective study. Great evidence in patients with erectile dysfunction
Pavone C, Castrianni D, Romeo S, Napoli E, Usala M, Gambino G, Scaturro D, Mauro GL. Urologia. 2013 Feb 18;0(0):0. doi: 10.5301/RU.2013.10756. [Epub ahead of print]

Source

A.O.U.P. "Paolo Giaccone", Dipartimento Materno-Infantile, Andrologia e Urologia, U.O.C Urologia, Palermo - Italy.

Abstract

Our phase-one prospective study wants to evaluate the safety and tolerability of TECAR therapy in the treatment of Peyronie's disease. From June 2011 to September 2012 we enrolled 70 patients. Each patient had been previously subjected to andrological examination, to a questionnaire for the evaluation of IPP and ED, and the SF-36 (V1) for the evaluation of the general state of health. The evaluation of pain was made using the VAS scale of pain. Every patient was subjected to TECAR treatment of the fibrotic plaque (both in resistive mode and in capacitive mode) for a total of three sessions carried out on consecutive days. We recorded a good compliance by patients; none of them reported side effects. Pain was decreased by the technique in 80% of the cases.The whole sample completed the study. Surprisingly enough those patients who complained also of erectile dysfunction, reported an improvement in sexual potency.